Stock 301230 PHARMARESOURCES (SHANGHAI) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings PharmaResources (Shanghai) Co., Ltd.

Equities

301230

CNE1000065Q9

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 30/05/2024 BST 		5-day change 1st Jan Change
32.87 CNY +1.73% Intraday chart for PharmaResources (Shanghai) Co., Ltd. -2.72% -8.18%
04-25 PharmaResources Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-24 PharmaResources Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PHARMARESOURCES (SHANGHAI) CO., LTD. Stock PharmaResources (Shanghai) Co., Ltd.
-8.18% 477M -
MODERNA, INC. Stock Moderna, Inc.
+43.36% 58.06B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 40.53B
B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.99B
A
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.7B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.56B
C
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.98B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.17B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.92B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 301230 Stock
  4. Ratings PharmaResources (Shanghai) Co., Ltd.